Stocks scoring 0–25 beat the S&P 500
39.9% of the time over the next three months, since 2015.
How we measured this →
7
hedge funds
hold it · 2 added, 4 trimmed
Cross-source blend of hedge-fund breadth, Congress trades, and insider Form 4s. ·
how the score works
Market cap
$3.0B
Industry
Biotechnology
Sector
Healthcare
Exchange
NasdaqGS
About ACADIA PHARMACEUTICALS INC
ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of medicines for neurological and rare disease in North America. The company offers NUPLAZID (pimavanserin), a selective serotonin inverse agonist/antagonist for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis; and DAYBUE, a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 to treat the symptoms of Rett syndrome by reducing neuroinflammation and supporting synaptic function. It also develops remlifanserin,…
Who's behind the signal
Every informed buyer we can see on ACAD, across all three feeds.
No significant Form 4 insider activity in the window.
Congressional trades · 2 on record
Disclosures from 2020-09-08 to 2022-06-16
The newest disclosure we hold for this stock is 2022-06-16.
That is the end of our data, not necessarily the end of the trading — our
bulk STOCK Act archive stops there and newer filings arrive through a
separate live feed. Treat the absence of recent rows as “not covered”,
not as “no trades”.
Not a model pick — but on our radar.
ACADIA PHARMACEUTICALS INC isn't in the top-10 model right now, but 7 tracked investors hold it. Everything below is real signal from public filings — treat this as a watch candidate, not a conviction call.
7
Investors
0
New positions
2
Increasing
4
Decreasing
1
Unchanged
Price History
Loading price data...
Ctrl/⌘ + scroll or pinch to zoom · drag to measure · double-click to resetPinch to zoom · drag sideways to move through time
▲
A member of Congress bought
▼
A member sold
Return: High: Low:
Markers sit on the transaction date the member disclosed, snapped to the
nearest close on the chart. They are not the date the public found out — that
came later, and
the gap is its own page.
Every marker is listed by name in the table above.
Who's Holding This Stock
Position sizes and recent activity from tracked institutional investors
How much of each investor's portfolio is allocated to ACADIA PHARMACEUTICALS INC
⚠ Disclaimer: This page is for informational purposes only. Holdings data from SEC EDGAR 13F filings, delayed up to 135 days. Not a recommendation to buy or sell ACADIA PHARMACEUTICALS INC or any security.